<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is regularly associated with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp>) and has been extensively documented as causal in <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently it has become evident that this virus is associated or handled differently in patients with a variety of immunological disorders </plain></SENT>
<SENT sid="2" pm="."><plain>If the mechanisms that normally limit the effects of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> are blunted, as in <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, antibody responses to EBV induced cellular antigens are significantly higher than in healthy individuals </plain></SENT>
<SENT sid="3" pm="."><plain>In the host with more profound immunosuppression a polyclonal B cell lymphoproliferation takes place which may progress to the monoclonal proliferation of true <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>